Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab
Status:
RECRUITING
Trial end date:
2027-01-03
Target enrollment:
Participant gender:
Summary
Evaluate the objective response rate (ORR) of AK104 combined with chemotherapy and cetuximab or bevacizumab in second-line treatment of MSS type advanced colorectal cancer
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University